- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
ProQR Announces Planned Changes to Board Composition
Two board members to rotate off as company advances clinical programs and focuses on long-term succession planning.
Published on Feb. 9, 2026
Got story updates? Submit your updates here. ›
ProQR Therapeutics N.V., a clinical-stage company dedicated to transformative RNA therapies, announced that Dinko Valerio, a co-founder of the company, and Alison Lawton will rotate off the Board at the company's next Annual General Meeting as their terms conclude. The planned changes reflect ProQR's development as it advances its clinical programs and its commitment to strong corporate governance and long-term succession planning.
Why it matters
The changes to ProQR's board composition are part of the company's ongoing efforts to ensure it maintains the right balance of skills, experience, and perspectives to support its long-term strategic objectives as it continues to advance its clinical pipeline of RNA-based therapies.
The details
An executive search firm has been engaged to help ProQR identify candidates to be nominated to the board to support long-term value creation. The company noted that the planned changes are a result of its regular review of board composition as part of its governance practices.
- ProQR's next Annual General Meeting (AGM) is when Dinko Valerio and Alison Lawton will rotate off the board as their terms conclude.
The players
ProQR Therapeutics N.V.
A clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform.
Dinko Valerio
A co-founder of ProQR Therapeutics who is rotating off the board.
Alison Lawton
A board member of ProQR Therapeutics who is rotating off the board.
James Shannon, MD
Chairperson of the Board of ProQR Therapeutics.
Daniel A. de Boer
Founder and Chief Executive Officer of ProQR.
What they’re saying
“On behalf of the Board, I would like to sincerely thank Dinko for his leadership, which has played a central role in shaping ProQR's vision and strategy, and Alison for her insight, dedication, and many valuable contributions to the Company during her tenure. Their efforts have had a meaningful impact on ProQR, and we are deeply grateful for their expertise.”
— James Shannon, MD, Chairperson of the Board of ProQR Therapeutics (biospace.com)
“Dinko and Alison have brought meaningful perspective and presence to the Board. I have greatly appreciated their insights and contributions, and I look forward to continuing to work closely with the Board as we execute our strategy and advance our clinical and pipeline programs.”
— Daniel A. de Boer, Founder and Chief Executive Officer of ProQR (biospace.com)
What’s next
An executive search firm has been engaged to assist ProQR in identifying candidates to be nominated to the Board to support long-term value creation for all its stakeholders.
The takeaway
The planned changes to ProQR's board composition reflect the company's commitment to strong corporate governance and long-term succession planning as it continues to advance its clinical pipeline of transformative RNA therapies.
